Nutriband Inc.
NASDAQ:NTRBBiotechnology
+$0.85 today
- Market cap
- $58.59M
- Beta
- 1.97
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$0.66
Volume 0.03M
Average 0.01M
NTRB Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Nutriband Inc.NASDAQ: NTRB
Research & Development · Q1 FY2026 · quarter ended Apr 2026
Research & development declines year over year
Q1 FY2026 research & development of $247.26K fell 63.8% year over year, behind the -48.6% change in trailing-twelve-month research & development. Sequentially, it rose 31.5% from the prior quarter. Over 3 fiscal years it compounded at +24.4% a year.
Context
- Research & development amounted to 92.9% of revenue in FY2025, down 52.9 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -63.8% toward the trailing-twelve-month pace of -48.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 1.89M USD
- Year-over-year change
- -39.4%
- 4-year CAGR
- +46.4%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2026-01-31 | 1.89M | -39.4% |
| FY2024 | 2025-01-31 | 3.12M | +59.1% |
| FY2023 | 2024-01-31 | 1.96M | +99.6% |
| FY2022 | 2023-01-31 | 982.23K | +138.8% |
| FY2021 | 2022-01-31 | 411.38K | — |
Research & Development vs competitors
How NTRB compares with its peers on the latest reported figures
- NTRB's LTM Apr 2026 research & development of $1.45M is the lowest of the 9 companies compared; the peer median is $35.53M.
- Its year-over-year change of -48.6% is the 6th highest of 8, against a peer median of -5.4%.
- Research & development amounts to 80.7% of revenue for NTRB, versus a peer median of 1163.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $106.27M | -5.4% | +24.0% | 1163.2% | |
| LTM Mar 2026 | $93.8M | -4.5% | +11.6% | — | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $59.66M | -11.8% | +35.8% | — |
| LTM Mar 2026 | $40.98M | +3.6% | +14.5% | — | |
| LTM Jun 2024 | $30.07M | — | -35.3% | 3686.7% | |
| LTM Mar 2026 | $23.02M | -48.6% | -81.3% | — | |
| LTM Mar 2026 | $10.72M | +1.7% | +6.8% | — | |
| LTM Mar 2026 | $8.51M | -76.4% | -55.5% | 12.9% | |
| LTM Apr 2026 | $1.45M | -48.6% | +24.4% | 80.7% | |
| Peer median (excluding NTRB) | $35.53M | -5.4% | +9.2% | 1163.2% | |
Competitors are the stored peer set for NTRB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Jan 2022 | FY2022 Jan 2023 | FY2023 Jan 2024 | FY2024 Jan 2025 | FY2025 Jan 2026 |
|---|---|---|---|---|---|
| Revenue | 1.42M | 2.08M | 2.09M | 2.14M | 2.04M |
| Cost of Revenue | 917.84K | 1.33M | 1.22M | 1.44M | 1.47M |
| Gross Profit | 504.31K | 750.41K | 862.11K | 699.3K | 566.31K |
| Gross Margin | 35.5% | 36.1% | 41.3% | 32.7% | 27.8% |
| Research & Development | 411.38K | 982.23K | 1.96M | 3.12M | 1.89M |
| Selling, General & Admin | 4.02M | 3.92M | 3.77M | 4.27M | 6.99M |
| Operating Expenses | 4.43M | 4.9M | 5.73M | 7.39M | 8.88M |
| Depreciation & Amortization | 318.26K | 368.96K | 287.72K | 285.05K | 193.8K |
| EBITDA | (5.74M) | (4.11M) | (5.12M) | (10.18M) | (8.01M) |
| EBITDA Margin | -403.6% | -197.5% | -245.6% | -475.5% | -393.5% |
| Operating Income | (3.93M) | (4.15M) | (4.87M) | (6.69M) | (8.32M) |
| Operating Margin | -276.3% | -199.5% | -233.6% | -312.6% | -408.4% |
| Interest Income | 0 | 0 | 16.85K | 191.67K | 0 |
| Interest Expense | 118.42K | 8.29K | 75.82K | 21.41K | 22.54K |
| Other Income / Expenses | (2.25M) | (335.62K) | (613.39K) | (3.79M) | 88.33K |
| Income Before Tax | (6.18M) | (4.48M) | (5.49M) | (10.48M) | (8.23M) |
| Pre-Tax Margin | -434.3% | -215.6% | -263.0% | -489.9% | -404.1% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (8.42M) | (4.81M) | (5.49M) | (10.48M) | (8.23M) |
| Net Margin | -592.2% | -231.3% | -263.0% | -489.9% | -404.1% |
| EPS (Basic) | (1.06) | (0.57) | (0.69) | (0.99) | (2.58) |
| EPS (Diluted) | (1.06) | (0.57) | (0.69) | (0.99) | (2.58) |
| Weighted Avg Shares | 7.93M | 8.46M | 7.95M | 10.61M | 11.64M |
| Weighted Avg Shares (Diluted) | 7.93M | 8.46M | 7.95M | 10.61M | 11.64M |
Nutriband Inc.
NASDAQ:NTRB
Intrinsic Alpha fair value
Locked
Current Price
$4.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.